Inhibitory effects of parthenolide on the activity of NF-κB in multiple myeloma via targeting TRAF6

Fan-Cong Kong1, Jing-Qiong Zhang2, Chen Zeng1

  • 1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

Insights

Parthenolide (PTL) inhibits nuclear factor-kappa B (NF-κB) signaling in multiple myeloma (MM) by binding to TRAF6. This mechanism suppresses MM cell proliferation and induces apoptosis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Nuclear factor-kappa B (NF-κB) signaling is crucial in multiple myeloma (MM) pathogenesis.
  • Parthenolide (PTL) is a compound with potential anti-cancer properties.
  • Understanding PTL's mechanism in MM is vital for therapeutic development.

Purpose of the Study:

  • To elucidate the inhibitory mechanism of PTL on NF-κB activity in MM.
  • To investigate PTL's effects on MM cell proliferation, cell cycle, and apoptosis.
  • To determine the direct molecular target of PTL in the NF-κB pathway.

Main Methods:

  • Human multiple myeloma RPMI 8226 cells were treated with PTL.
  • Cell proliferation was assessed using MTT assay.
  • Cell cycle and apoptosis were analyzed by flow cytometry.
  • Protein ubiquitination, IκB-α, and p65 levels were measured by immunoprecipitation and Western blotting.
  • Immunofluorescence was used to examine p65 localization.
  • Autodock software predicted PTL-TRAF6 binding.

Main Results:

  • PTL treatment decreased ubiquitinated Nemo and TRAF6 levels.
  • PTL increased IκB-α expression and reduced nuclear p65.
  • NF-κB activity was inhibited by PTL.
  • PTL suppressed MM cell proliferation, induced apoptosis, and blocked cell cycle progression.
  • PTL was predicted to bind directly and tightly to TRAF6.

Conclusions:

  • PTL inhibits NF-κB activation by directly binding to TRAF6.
  • This interaction leads to the suppression of MM cell proliferation.
  • PTL effectively induces apoptosis in multiple myeloma cells, suggesting therapeutic potential.

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.6K
NF-kB-dependent Signaling Pathway02:26

NF-kB-dependent Signaling Pathway

2.5K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
11.0K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
8.0K